Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy
19 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
“CD38 Therapeutics” Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic considerations○ Clinical...
Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company
12 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its...
Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain
10 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark...
Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration
05 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
ZTlido® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in MaySP-102 pivotal phase 3 trial remains on track for completion in H1 2020ZTlido® 5.4% (3 X...
Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships
04 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 04, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd....
Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).
21 mai 2019 18h25 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB...
Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations
16 avr. 2019 09h00 HE
|
Sorrento Therapeutics, Inc.
Cannabidiol (CBD) material from virtually THC-free (<0.3%) hemp plants sourcesExcipients on the FDA approved GRAS (Generally Regarded As Safe) listWater soluble formulations with target...
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
15 avr. 2019 04h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...
Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration
10 avr. 2019 09h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study...
CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
11 mars 2019 12h54 HE
|
Sorrento Therapeutics, Inc.
SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sorrento Therapeutics, Inc. (Nasdaq: SRNE), please note that in the...